NOV 17, 202650 MINS READ
Research-grade creatine phosphate (CrP) exists predominantly as the disodium salt dihydrate (C₄H₈N₃O₅PNa₂·2H₂O) or trihydrate form, with molecular weight ranging from 255.1 Da (anhydrous) to 291.1 Da (trihydrate) depending on hydration state 3. The compound features a guanidinium moiety linked to an N-phosphoryl group, conferring high-energy phosphate bond characteristics (ΔG°' ≈ -43.1 kJ/mol under physiological conditions). Structural studies reveal that the phosphate group can adopt both the standard N-phosphoryl configuration and, in hydrated crystalline forms, a 2,2-dihydroxypropionate tautomer 19. This structural polymorphism directly impacts solubility profiles: anhydrous forms exhibit limited aqueous solubility (<50 mg/mL at 25°C), whereas the disodium trihydrate demonstrates enhanced solubility exceeding 200 mg/mL 2,3.
Key physicochemical parameters for research-grade material include:
The compound's hygroscopic nature necessitates storage under inert atmosphere (nitrogen or argon) at 2–8°C to prevent hydrolysis and oxidative degradation 4. Spectroscopic characterization via ³¹P-NMR reveals a characteristic singlet at δ 2.8–3.2 ppm (relative to H₃PO₄), while UV absorbance maxima occur at 210 nm (ε = 8,200 M⁻¹cm⁻¹) 1,5.
The enzymatic route represents the gold standard for research-grade synthesis due to superior stereoselectivity and minimal side-product formation 1,17. The process employs creatine kinase (CK, EC 2.7.3.2) to catalyze phosphoryl transfer from ATP or alternative phosphate donors to creatine. A landmark method developed by Beaucamp et al. utilizes 3-phosphoglyceric acid (3-PGA) as the phosphate source in the presence of catalytic ATP (0.5–2.0 mM) and crude muscle extract containing endogenous CK, phosphoglycerate kinase, and phosphoglycerate mutase 1.
Optimized reaction conditions:
This approach achieves molar yields of 78–85% with purity exceeding 98.5% after single-step ion-exchange purification 1. The brief heat treatment (70–100°C) denatures enzymes while preserving CrP integrity, as the N-phosphoryl bond exhibits remarkable thermal stability under alkaline conditions (t₁/₂ > 6 hours at 95°C, pH 9.0) 1,17.
Chemical synthesis employs phosphorus oxychloride (POCl₃) as the phosphorylating agent, reacting with creatine or creatinine precursors 1,12,13. The modern continuous-flow variant addresses safety concerns and improves atom economy:
Step 1 – Creatinine phosphorylation: Creatinine (10 g, 88.4 mmol) is dissolved in anhydrous dichloromethane (100 mL) and reacted with POCl₃ (450 g, 2.93 mol, 33-fold excess) at 105°C for 30 minutes under reflux 12. Excess POCl₃ is removed via vacuum distillation (bp 105°C/760 mmHg), yielding creatinine phosphoryl chloride as a viscous intermediate.
Step 2 – Purification of phosphoryl chloride intermediate: The crude product is redissolved in dichloromethane (100 mL), stirred for 2 hours, and filtered to remove polymeric impurities. Addition of petroleum ether (200 mL) precipitates purified creatinine phosphoryl chloride (yield 65–72%) 12.
Step 3 – Alkaline hydrolysis: The purified intermediate is added dropwise to ice-cold 4.0 M NaOH (molar ratio 1:4.2) with vigorous stirring, maintaining temperature below 10°C. Hydrolysis proceeds for 1.5–2.0 hours, converting the phosphoryl chloride to disodium creatine phosphate 12,13. The aqueous phase is separated, treated with activated cationic resin (Amberlite IR-120, H⁺ form) to pH 9.0–9.5, and filtered through 0.22 μm membranes 13.
Step 4 – Crystallization: Addition of 95% ethanol (4:1 v/v ratio) induces crystallization at 4°C over 12–18 hours. The product is collected by centrifugation (3,000 × g, 10 min) and vacuum-dried at 40°C for 24 hours, yielding 99.2–99.8% pure disodium creatine phosphate dihydrate 3,12.
Continuous-flow microreactor adaptation reduces POCl₃ consumption by 60% (from 33-fold to 12-fold excess) and shortens reaction time to 8–15 minutes, while maintaining >99.0% purity and 68–74% overall yield 13.
High-purity creatine phosphate for research applications demands rigorous removal of inorganic phosphate (Pi), creatine, creatinine, and residual salts 3,4. The optimized protocol employs strong anion-exchange resin (Dowex 1×8, Cl⁻ form, 100–200 mesh):
Column preparation and loading: A glass column (2.5 cm i.d. × 30 cm) is packed with 150 mL resin and equilibrated with 0.05 M NaCl (pH 8.0). Crude creatine phosphate solution (40–70% ethanol-pretreated to precipitate neutral impurities) is loaded at 2.0 mL/min 3.
Gradient elution protocol:
Fractions containing CrP (identified by ³¹P-NMR or enzymatic assay) are pooled, concentrated via rotary evaporation (bath temperature ≤35°C), and crystallized by ethanol addition. This single-pass purification elevates purity from 92–95% to ≥99.5%, with recovery rates of 82–88% 3.
Research-grade certification requires multi-method analytical validation 4,5:
Method 1 – Reversed-phase HPLC with UV detection:
Method 2 – Ion-pair HPLC with evaporative light scattering detection (ELSD): This method enables simultaneous quantification of CrP and inorganic phosphate without chromophore requirements 4:
Acceptance criteria for research-grade material:
Functional validation via creatine kinase-coupled assay confirms biological activity 1,8:
Assay principle: CrP + ADP ⇌ Creatine + ATP (catalyzed by CK) ATP + Glucose → ADP + Glucose-6-phosphate (catalyzed by hexokinase) Glucose-6-phosphate + NADP⁺ → 6-Phosphogluconate + NADPH (catalyzed by G6PDH)
NADPH formation is monitored at 340 nm (ε = 6,220 M⁻¹cm⁻¹). Research-grade CrP should yield ≥98% of theoretical NADPH production, confirming intact phosphoryl transfer capability 1.
Creatine phosphate serves as the preferred ATP-regenerating substrate in coupled enzyme assays requiring sustained ATP concentrations 1,16. In kinase activity assays (e.g., protein kinases, aminoacyl-tRNA synthetases), the CK/CrP system maintains ATP:ADP ratios >100:1 for extended periods (>4 hours at 25°C), preventing product inhibition and enabling accurate kinetic parameter determination 1. Typical assay composition includes:
This system is indispensable in high-throughput screening campaigns targeting ATP-dependent enzymes, where it reduces reagent costs by 70–85% compared to direct ATP supplementation 1,16.
Creatine phosphate and its membrane-permeable prodrugs (e.g., salicyl alcohol esters, cyclocreatine phosphate analogs) are extensively investigated for myocardial protection during ischemia-reperfusion injury 2,6,7. In isolated perfused heart models (Langendorff preparation), exogenous CrP administration (5–10 mM in perfusate) preserves:
Prodrug strategies employing acyloxyalkyl ester moieties (e.g., Formula I compounds in 2) enhance cellular uptake 15–30-fold compared to free CrP, enabling oral bioavailability and systemic cardioprotection in rodent models 2,6. Phase II clinical trials (NCT02837328) are evaluating these prodrugs for acute myocardial infarction, with preliminary data showing 22% reduction in infarct size (measured by cardiac MRI) when administered within 6 hours of symptom onset 2.
The creatine kinase system plays a critical role in neuronal energy homeostasis, and CrP supplementation strategies are under investigation for Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) 16,18. In cellular models:
Huntington's disease (HD) striatal neurons: CrP (5 mM) or cyclocreatine (2 mM) treatment increases ATP/ADP ratios from 2.1 ± 0.3 to 4.8 ± 0.5, delays mitochondrial membrane potential collapse (ΔΨm depolarization reduced by 55%), and extends cell viability by 48–72 hours under glutamate excitotoxicity (100 μM) 16,18.
Parkinson's disease models (MPTP-treated mice): Oral cyclocreatine (1% w/w in diet, equivalent to ~1.5 g/kg/day) for 4 weeks preserves:
The neuroprotective mechanism involves stabilization of mitochondrial creatine kinase (
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| BOEHRINGER MANNHEIM GMBH | Industrial-scale biochemical reagent manufacturing for bioenergetics research, ATP regeneration assays, and pharmaceutical intermediate production requiring high-purity creatine phosphate standards. | Enzymatic Creatine Phosphate Synthesis System | Achieves 78-85% molar yield with >98.5% purity through enzymatic phosphorylation using 3-phosphoglyceric acid and catalytic ATP, enabling cost-effective large-scale production without phosphoryl chloride hazards. |
| XENOPORT INC. | Cardioprotection therapy for acute myocardial infarction, ischemia-reperfusion injury treatment in isolated perfused heart models, and systemic energy metabolism disorders requiring enhanced bioavailability. | Membrane-Permeable Creatine Phosphate Prodrugs | Acyloxyalkyl ester prodrugs enhance cellular uptake 15-30-fold compared to free creatine phosphate, achieving 22% reduction in myocardial infarct size and preserving 78-85% left ventricular function after ischemia-reperfusion injury. |
| Southwest Pharmaceutical Co., Ltd. | Pharmaceutical-grade creatine phosphate production for injectable formulations, quality control of research-grade biochemical reagents, and intermediate purification in multi-step synthesis processes. | High-Purity Creatine Phosphate Sodium Purification Technology | Ion-exchange chromatography purification achieves ≥99.5% purity with 82-88% recovery rate, eliminating sulfate and barium contamination while meeting pharmaceutical-grade specifications (creatine <0.5%, creatinine <0.2%). |
| SHANGHAI HUATUO MEDICAL SCIENCE CO. LTD. | Quality control and analytical validation for research-grade creatine phosphate certification, pharmaceutical manufacturing process monitoring, and impurity profiling in enzymatic and chemical synthesis routes. | HPLC-ELSD Impurity Detection System | Evaporative light scattering detection enables simultaneous quantification of creatine phosphate and inorganic phosphate with detection limits of 0.02% and 0.01% respectively, without requiring chromophore groups. |
| AVICENA GROUP INC. | Neurodegenerative disease research including Huntington's disease, Parkinson's disease, and ALS models; neuroprotection studies involving mitochondrial energy homeostasis and excitotoxicity prevention in neuronal cell cultures. | Cyclocreatine Neuroprotection Therapy | Cyclocreatine treatment (1% w/w dietary supplementation) preserves 68% striatal dopamine content and 72% tyrosine hydroxylase-positive neuron survival in MPTP-treated Parkinson's models, while increasing ATP/ADP ratios from 2.1 to 4.8 in Huntington's disease neurons. |